154 related articles for article (PubMed ID: 8339212)
41. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
42. The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography.
Dapling RB; Snowden JA; West J; Talbot JF; Nelson ME; Greaves M
Clin Lab Haematol; 1996 Dec; 18(4):277-9. PubMed ID: 9054702
[TBL] [Abstract][Full Text] [Related]
43. Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML.
McCarthy LJ; Graves VL; Eigen H; McGuire WA
Transfus Med; 1991 Sep; 1(3):187-9. PubMed ID: 9259847
[TBL] [Abstract][Full Text] [Related]
44. Plateletpheresis: Nonoperative Management of Symptomatic Carotid Thrombosis in a Patient with Reactive Thrombocytosis.
Martínez RC; Quaynor S; Alkhalifah M; Goldenberg FD
World Neurosurg; 2018 Jun; 114():126-129. PubMed ID: 29555611
[TBL] [Abstract][Full Text] [Related]
45. Chronic myelocytic leukemia and the myeloproliferative diseases during the child-bearing years.
Miller JB
J Reprod Med; 1976 Oct; 17(4):217-24. PubMed ID: 1068296
[TBL] [Abstract][Full Text] [Related]
46. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
47. Platelet apheresis for digital gangrene due to thrombocytosis in chronic myeloid leukaemia.
Win N; Mitchell DC
Clin Lab Haematol; 2001 Feb; 23(1):65-6. PubMed ID: 11422234
[TBL] [Abstract][Full Text] [Related]
48. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
49. Potential role for platelet apheresis for post-liver transplant thrombocytosis complicating portal vein thrombosis.
Au WY; Liu CL; Lo CM; Fan ST; Ma SK
J Clin Apher; 2004; 19(4):192-6. PubMed ID: 15597348
[TBL] [Abstract][Full Text] [Related]
50. Busulfan, antimetabolites, radiotherapy, and cost of treatment in chronic myelocytic leukemia. A non-controlled, non-randomized monocenter study with historical controls.
Ogier C; Reizenstein P
Acta Med Scand; 1981; 210(5):409-13. PubMed ID: 6950660
[TBL] [Abstract][Full Text] [Related]
51. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622
[TBL] [Abstract][Full Text] [Related]
52. Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
Guilhot F; Ahmad M; Mahon FX; Dreyfus B; Brizard A; Huret JL; Kitzis A; Tanzer J
Nouv Rev Fr Hematol (1978); 1990; 32(5):287-8. PubMed ID: 2099398
[TBL] [Abstract][Full Text] [Related]
53. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
[TBL] [Abstract][Full Text] [Related]
54. Bleeding and thrombosis in the myeloproliferative disorders.
Schafer AI
Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
[TBL] [Abstract][Full Text] [Related]
55. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Silver RT
Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
[TBL] [Abstract][Full Text] [Related]
56. Hydroxyurea therapy in chronic myelogenous leukemia.
Kennedy BJ
Cancer; 1972 Apr; 29(4):1052-6. PubMed ID: 4552811
[No Abstract] [Full Text] [Related]
57. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
58. Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.
Sagripanti A; Ferretti A; Nicolini A; Carpi A
Biomed Pharmacother; 1996; 50(8):376-82. PubMed ID: 8952859
[TBL] [Abstract][Full Text] [Related]
59. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
60. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
